Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis

NCT00748501 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT00748501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00748501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis
Lead sponsor
Sangamo Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
June 30, 2010
Enrollment
45 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis